Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Revenue and Financial Performance — Preliminary Q2 2026 Disclosure
REGN logo

Regeneron Expects $127 Million Charge to Reduce Quarterly EPS by $1.00

REGN8-KFiling Date: 7/6/2026
Regeneron Pharmaceuticals, Inc.
Description

What this story covers

Regeneron disclosed a preliminary $127 million pre-tax IPR&D charge for Q2 2026 due to strategic collaborations. This will reduce diluted EPS by approximately $1.00, reflecting a commitment to external innovation despite a strong $14 billion revenue base.

Story snapshot

CompanyRegeneron Pharmaceuticals, Inc.
TickerREGN
VariantStandard detailed
Duration4:35
Filing type8-K
PeriodQ3 2026
IndustryHealthcare & Pharmaceuticals
Accession0001104659-26-080562
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing8-KView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in